IQuity is developing a health-care analytics platform that will mine large databases to predict and monitor chronic disease across large populations, transforming the company from a genomics test-maker to an "integrated data science company."
The Nashville-based genomics company has developed three genomic assays based on its IQIsolate process for multiple sclerosis, for irritable bowel syndrome and irritable bowel disease, and fibromyalgia. "Those tests were each built using about 1,000 patients and we can achieve very high accuracy levels - greater than 90% - but ... it takes a long time and a lot of money to be able to build-out those tests," iQuity CEO Chase Spurlock told Medtech Insight. "So we asked the question: If we used just a population-level data approach - where we can, with a few clicks of a mouse, capture data on tens of thousands of patients - could we actually have higher levels of accuracy
